Concord Drugs opened higher at ₹74.45, compared with its previous close of ₹71.11. In the last trading session on 12 Nov 2026, the stock traded between ₹71.54 and ₹74.45, with an average traded price of ₹72.85. It showed an upward intraday trend.
An investment of ₹10,000 made 5 years ago in Concord Drugs is now worth
₹ 24,439.00
Giving a profit of
₹ 14,439.00 (144.39%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+1.84 (+2.59%)
Day High
₹74.45
Day Low
₹71.54
Day Open
₹74.45
Prev Close
₹71.11
Volume
948
Value Traded
₹0.01 Cr
1W Return
7.28%
1M Return
3.62%
3M Return
-2.62%
6M Return
-13.34%
1Y Return
-14.69%
Market Cap (₹ Cr.)
96
PE Ratio
45.60
PB Ratio
2.01
Dividend Yield
-
ROE
2.17%
ROCE
5.92%
Book Value (₹)
35.43
Face Value (₹)
10.00
EPS (TTM)
0.85
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
7.28%
6 Weeks
-
1 Month
3.62%
3 Months
-2.62%
9 Months
-12.75%
Concord Drugs Q2FY27 Results: Net profit surges 618% YoY to ₹1.09 crore
Net profit surged 618% YoY to ₹1.09 crore in Q2FY27. Revenue from operations increased 105% YoY to ₹20.74 crore. Operating cash flow remained negative at ₹7.48 crore for H1FY27 due to rising receivables.
TodayConcord Drugs passes all seven resolutions at 31st annual general meeting
All seven resolutions at Concord Drugs' 31st AGM passed with 99.9999% support. Promoters voted 100% of their 59.39 lakh shares in favor of all items. Public non-institutional shareholders voted only 6.062% of their holdings. Directors S. Nagi Reddy, Hareesh Kumar Solleti, and Sumeela Kasu reappointed.
1mo agoConcord Drugs approves FY26 financials, sets September 30 AGM date
Concord Drugs board approved audited standalone and consolidated financial statements for FY26. The 31st Annual General Meeting is scheduled for September 30, 2026 via video conference. Record date for remote e-voting eligibility is set as September 23, 2026. S. Nagi Reddy proposed for re-appointment as Chairman and Managing Director.
2mo agoConcord Drugs sets Sep 23 record date for 31st AGM
Concord Drugs sets September 23, 2026, as the record date for its 31st AGM. The annual general meeting is scheduled for September 30, 2026, via VC/OAVM. Book closure period runs from September 24 to September 30, 2026. Eligible shareholders can cast electronic votes during the meeting.
2mo agoConcord Drugs provides web link to access FY26 annual report
Concord Drugs provides web link to FY26 annual report for shareholders with unregistered emails. Disclosure made under Regulation 36(1)(b) of SEBI LODR Regulations, 2015. 31st AGM scheduled for September 30, 2026, via video conferencing. Company urges investors to update email IDs with depository participants.
2mo agoConcord Drugs Q1 Results: Net profit surges 901% YoY to ₹1.11 crore
Concord Drugs reported a 901% YoY surge in standalone net profit to ₹1.11 crore for Q1FY27. Consolidated profits also jumped significantly. The growth outpaced a 33% equity dilution from a preferential share allotment, driving EPS up to ₹0.84.
3mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,899.30 | +0.76% | ₹4,55,705.69 | 41.20 | +9.65% | |
| ₹11,495.00 | +0.09% | ₹3,05,156.13 | 90.40 | +76.30% | |
| ₹4,685.20 | -0.89% | ₹1,78,209.95 | 85.50 | +22.50% | |
| ₹2,427.00 | +1.13% | ₹1,31,133.78 | 97.10 | +145.34% | |
| ₹1,204.50 | -0.12% | ₹1,20,149.34 | 28.00 | +26.60% | |
| ₹1,388.30 | +0.12% | ₹1,15,878.66 | 42.00 | +12.91% | |
| ₹1,409.80 | +0.11% | ₹1,13,891.88 | 39.90 | -7.21% | |
| ₹2,663.30 | +0.94% | ₹1,10,006.30 | 48.10 | +17.33% | |
| ₹1,808.90 | +0.09% | ₹1,04,080.11 | 26.00 | +52.83% | |
| ₹2,019.10 | +0.20% | ₹92,331.42 | 17.60 | -0.73% | |
| ₹2,639.00 | -0.78% | ₹74,479.09 | 51.60 | +42.82% | |
| ₹5,194.00 | -2.04% | ₹62,102.06 | 30.50 | -9.94% |
An investment of ₹10,000 made 5 years ago in Concord Drugs is now worth
₹ 24,439.00
Giving a profit of
₹ 14,439.00 (144.39%)
Note: Past profits do not guarantee future returns.
